Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Cyclo Therapeutics, Inc. today reported its financial results for the second quarter 2023.
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results Read More »
Uncategorized
Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates
Biotricity Inc. today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.
Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease
Research has shown that a novel antibody generated to target an ‘essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).
ImmunoBrain Checkpoint Announces Expansion of Board of Directors with Appointment of James M. Mackay, Ph.D.
ImmunoBrain Checkpoint Inc.today announced the appointment of James M. Mackay , Ph.D., to the Board of Directors. Mackay brings decades of biopharma leadership experience to the Company’s Board.
Clario and AliveCor collaborate to offer advanced, trial-focused six-lead ECG solutions for monitoring in decentralized clinical trials
Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology.
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from its PROCLAIM trial, published in European Urology Oncology, showing that almost half of prostate cancer patients with clinically actionable pathogenic/likely pathogenic germline variants (PGVs) could be missing out on genetics-informed care due to restrictive criteria for genetic testing.
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer Read More »
Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference
Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane’s effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.
ExThera Medical Receives Certification for Medical Device Single Audit Program (MDSAP) and Recertification for International Organization for Standardization for Medical Devices (ISO 13485)
ExThera Medical Corporation announces it has received simultaneous certification per Medical Device Single Audit Program (MDSAP) and International Organization for Standardization (ISO 13485) requirements.
AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors
AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.
AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors Read More »
Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for cardiovascular machine learning-based notification software.